<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Steven Sankey on Medium]]></title>
        <description><![CDATA[Stories by Steven Sankey on Medium]]></description>
        <link>https://medium.com/@stevensankey?source=rss-1041e709ec62------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/2*EQJXDwQW0zCS3a13C_7GEg.jpeg</url>
            <title>Stories by Steven Sankey on Medium</title>
            <link>https://medium.com/@stevensankey?source=rss-1041e709ec62------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 15:06:19 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@stevensankey/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[SARS-CoV-2 Binds to ACE2: What are ACE2 Receptors?]]></title>
            <link>https://medium.com/@stevensankey/sars-cov-2-binds-to-ace2-what-are-ace2-receptors-8c400c37317f?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/8c400c37317f</guid>
            <category><![CDATA[sars-cov2]]></category>
            <category><![CDATA[physiology]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Sun, 16 Aug 2020 20:50:04 GMT</pubDate>
            <atom:updated>2020-08-16T20:50:04.190Z</atom:updated>
            <content:encoded><![CDATA[<p><em>SARS-CoV-2 binds to ACE2 receptors on our cells but what are ACE2 receptors and what do they do?</em></p><figure><img alt="Computer generated image of a globular virus." src="https://cdn-images-1.medium.com/max/1024/1*gXGCnWIUSB5NIAaBQzWFCQ.jpeg" /></figure><p>We’ve known for some months now that the novel coronavirus — SARS-CoV-2 — binds to ACE2 receptors on the surface of some of our cells. In fact, the first SARS-CoV, which caused an epidemic in 2002–3, was also <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287568/">found to bind</a> to these same ACE2 receptors. But what does this actually mean? And what are these ACE2 receptors and what do they even do?</p><h3>SARS-CoV-2 Binding</h3><p>You may be familiar with the typical representation we see in the media of a generic virus (like the one above) and this is actually quite accurate to the way coronaviruses look.</p><p>The term “coronavirus” is actually an umbrella term for a large subfamily of viruses called <a href="https://www.sciencedirect.com/topics/neuroscience/coronavirinae"><em>Coronavirinae</em></a>. All coronaviruses contain RNA (genetic material) within a spherical-like capsid which is covered in spike-like protrusions often referred to as spike proteins (sometimes scientists make it easy). These spike proteins are what facilitate these kind of viruses to bind to our cells and infect them (Fig.1).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*mR7uT2YkkWKdSkji8sDXvw.png" /><figcaption>Fig. 1: A 3D representation of a coronavirus, with the capsid in grey and spike proteins in red (image: <a href="https://phil.cdc.gov/">PHIL</a>).</figcaption></figure><p>The virus’ spike proteins are very specifically shaped and therefore need a very specific protein to bind with before they can infect a cell. They can’t just bind with anything. The most common analogy used for this is a lock and its key. In this analogy, these spike proteins are the key. But what about the lock?</p><p>Continuing with the analogy, the ACE2 receptors on some of our cells are the lock. The SARS-CoV-2 spike proteins have the ability to <a href="https://www.cell.com/cell/fulltext/S0092-8674(20)30262-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420302622%3Fshowall%3Dtrue">bind to ACE2 receptors</a> on the surface of our cells and thus ‘unlock’ the ability to fuse with our cells. Once bound, the virus capsid — its membrane — fuses to our cell’s membrane, which allows it to release its viral RNA into our cell, infecting it and essentially using it as a virus factory. You can imagine this as kind of like when a smaller bubble fuses with, and becomes part of, a larger bubble on your bathwater.</p><p>ACE2 receptors aren’t found on all of our cells but they are abundant. They are mostly found on lung, kidney, and other capillary-rich organs. They are <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287568/">also found on cells</a> in the small intestine, testes, and brain.</p><h3>What Are ACE2 Receptors?</h3><p>Angiotensin converting enzyme-2 — usually simplified to ACE2 because most scientists aren’t masochists — is a type I membrane-bound glycoprotein, which is a fancy way of saying ACE2 is basically a protein which is situated inside the cell membrane.</p><p>Many, many proteins lie in and on our cells’ membranes and they all serve an intended purpose. ACE2 is, as its name suggests, an enzyme which converts angiotensin I into angiotensin 1–9, and angiotensin II into angiotensin 1–7 (Fig. 2). Now that may sound very mundane but it’s actually a very important regulatory system.</p><figure><img alt="Fig. 2: ACE2 receptors in the cell membrane convert (angiotensin) Ang I into Ang 1–9, and Ang II into Ang 1–7." src="https://cdn-images-1.medium.com/max/600/1*Y0rF8y8B7fC5M9Q4wRlaQg.png" /><figcaption>Fig. 2: ACE2 receptors in the cell membrane convert (angiotensin) Ang I into Ang 1–9, and Ang II into Ang 1–7.</figcaption></figure><p><a href="https://www.frontiersin.org/articles/10.3389/fcimb.2020.00317/full">Angiotensin (Ang) I and Ang II</a> are protein hormones which are part of a regulatory system which helps to control things such water retention and blood pressure. So, what is the role of ACE2 in this regulatory system?</p><h3>What Is The Role of ACE2?</h3><p>So, we now know what ACE2 is and what ACE2 does, but what is the purpose of converting these protein hormones? To answer this we need to understand the regulatory system that ACE2 is a part of, beginning with the renin-angiotensin system (RAS). Stick with me here.</p><p>Renin, an enzyme secreted by the kidneys into the blood, converts angiotensinogen into Ang I. ACE (a related enzyme to ACE2) converts Ang I into Ang II. This is necessary as Ang II is a hormone that binds to (angiotensin II type 1) AT1 and (angiotensin II type 2) AT2 receptors in the cell membrane. This can result in the retention of sodium and water, vasoconstriction (narrowing of blood vessels therefore raising blood pressure), cell proliferation, and cell death. This is known as the <a href="https://www.frontiersin.org/articles/10.3389/fcimb.2020.00317/full">ACE/RAS pathway</a> (Fig. 3).</p><figure><img alt="Fig. 3: The ACE/RAS pathway. Renin converts angiotensinogen into Ang I. ACE then converts Ang I into Ang II." src="https://cdn-images-1.medium.com/max/600/1*mBefGjl2geIs1Un1xx423Q.png" /><figcaption>Fig. 3: The ACE/RAS pathway. Renin converts angiotensinogen into angiotensin (Ang) I. ACE then converts Ang I into Ang II. Ang II binds to either AT1 or AT2. Downstream processes can result in sodium and water retention, vasoconstriction, cell proliferation, and cell death.</figcaption></figure><p>Of course, we don’t want to retain sodium and water, and have high blood pressure forever, nor do we want all of these cells to either continuously proliferate or die. This is where the ACE2/Mas pathway regulates the ACE/RAS pathway just described. Don’t worry, we’re almost there.</p><p>As previously stated, ACE2 converts Ang I into Ang 1–9, and Ang II into Ang 1–7. This effectively prohibits the results of the ACE/RAS pathway by preventing Ang II from binding with AT1 and AT2. Ang 1–9 and Ang 1–7 can then bind (separately) with Mas protein receptors also in the cell membrane. The downstream processes of this Ang 1–9/Mas and Ang 1–7/Mas binding result in preventing cell death, vasodilation (widening of blood vessels and therefore lowering blood pressure), and inhibiting cell proliferation (Fig. 4).</p><figure><img alt="Fig. 4: The ACE2/Mas pathway. ACE2 converts Ang I into Ang 1–9 and Ang II into Ang1–7." src="https://cdn-images-1.medium.com/max/600/1*o8rf6nJJfdSt52SltWki1A.png" /><figcaption>Fig. 4: The ACE2/Mas pathway. ACE2 converts (angiotensin) Ang I into Ang 1–9 and Ang II into Ang 1–7. Ang 1–7 and Ang 1–9 (separately) bind to Mas receptors. This inhibits the ACE/RAS pathway and can result in cell protection, vasodilation, and antiproliferation.</figcaption></figure><p>Putting aside all the abbreviations we scientists love, what we have now is a more complete picture of a regulatory pathway for blood vessel constriction/dilation, water retention, cell proliferation, and cell death.</p><p>As the adage goes, too much of anything is a bad thing. Here, our ACE2 receptors are counterbalancing the deleterious effects of continued ACE/RAS activity: high blood pressure, excessive water retention, continuous cell division, and cell death (Fig. 5). Our ACE2 receptors moderate this process, preventing it from running out of control. This is actually a very common way our cells regulate many processes, by introducing an inhibiting factor and essentially restraining a process.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*6kv-RczqpKeDPWtNLFuv9A.png" /><figcaption>Fig. 5: ACE2 regulates the ACE/RAS pathway by converting Ang I into Ang 1–9 and Ang II into Ang 1–7. This inhibits the conversion of Ang I into Ang II by ACE and also inhibits Ang II that is produced by ACE from binding with AT1 and AT2. This aids in counterbalancing the deleterious effects of the ACE/RAS pathway.</figcaption></figure><p>So, what happens when we introduce a virus which binds to ACE2 and prevents it from performing its intended role as a counterbalance to this ACE/RAS pathway?</p><h3>Disruption of the ACE2/Mas Pathway</h3><p>By binding with our ACE2 receptors, SARS-CoV-2 is effectively acting as an inhibitor for the ACE2/Mas pathway. To predict what could occur in this event, we can look to research into the inhibition of ACE2 or production of dysfunctional ACE2, as these should produce comparable results.</p><p>Previous research has linked dysfunctional ACE2 receptors, meaning they can’t perform their function properly, to conditions such as hypertension, cardiovascular disease, strokes, and diabetes. And these make sense when we consider that ACE2 is the inhibitor of the ACE/RAS pathway, a pathway that results in constricting our blood vessels and causing high blood pressure (hypertension).</p><p>We do have medication that can fulfil the intended function of ACE2, known as <a href="https://www.bhf.org.uk/informationsupport/heart-matters-magazine/medical/drug-cabinet/arbs">angiotensin receptor blockers (ARBs)</a>. ARBs act as inhibitors for those AT1 receptors with which Ang II bind with. Research has shown that the use of ARBs can also result in the upregulation of ACE2. This would normally be considered a good thing in cases of hypertension, as the body is beginning to regulate itself again. However, in the case of SARS-CoV-2 this is a double-edged sword, as the more ACE2 that is produced by our cells <a href="https://www.frontiersin.org/articles/10.3389/fcimb.2020.00317/full">the more binding sites the SARS-CoV-2</a> virus has to infect our cells. This has the potential to lead to much higher viral loads which was <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC527336/">linked to poorer prognoses</a> in the 2002–3 SARS-CoV epidemic.</p><p>ACE2 doesn’t just regulate our blood pressure, though. It is well established as a factor in <a href="https://www.frontiersin.org/articles/10.3389/fcimb.2020.00317/full">preventing lung damage</a> such as cell death (apoptosis) and the formation of scar tissue (fibrosis). This is particularly true for the alveolar epithelial cells within our lungs. These alveolar epithelial cells are where our blood exchanges gases with the air we breathe in and out. With diminished ACE2 activity due to SARS-CoV-2 binding, these cells could begin to die more often, potentially leading to diminished gas exchange capability and contributing towards pneumonia (as I discussed further <a href="https://medium.com/@stevensankey/but-what-actually-is-coronavirus-5ccdad495f12">here</a>).</p><p>We have discussed that by inhibiting the ACE/RAS pathway, ACE2 inhibits cell proliferation. Any protein in the body that restrains or inhibits cell proliferation (cell division) is often found to be what is called a tumour suppressor. Tumours are the result of uncontrolled cell division. Therefore ACE2 can be regarded as a tumour suppressor. It is therefore reasonable to assume that where we have the inhibition, dysfunction, or downregulation of ACE2 we may also see tumours (including cancers). And this is exactly what research has suggested in some lung and breast cancers, with ACE2 being shown to restrain <a href="https://pubmed.ncbi.nlm.nih.gov/27460845/">non-small cell lung cancer</a> and inhibit <a href="https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1156-5">breast cancel cell migration</a>.</p><p>For more on how SARS-CoV-2 works and how it affects us more broadly, including our own immune response to it, you can check my previous article: <a href="https://medium.com/@stevensankey/but-what-actually-is-coronavirus-5ccdad495f12">But What Actually is Coronavirus?</a></p><h3>Further Reading</h3><p>Bhf.org.uk (2020). <em>Angiotensin receptor blockers (ARBs)</em>. Available at: https://www.bhf.org.uk/informationsupport/heart-matters-magazine/medical/drug-cabinet/arbs</p><p>Jia, H., Look, D., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane, C., Perlman, S. and McCray, P. (2005). ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. <em>Journal of Virology</em>, 79<strong>(23)</strong>, 14614–14621.</p><p>Samavati, L. and Uhal, B. (2020). ACE2, Much More Than Just a Receptor for SARS-COV-2. <em>Frontiers in Cellular and Infection Microbiology</em>, 10.</p><p>Walls, A., Park, Y., Tortorici, M., Wall, A., McGuire, A. and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. <em>Cell</em>, 181<strong>(2)</strong>, 281–292.e6.</p><p>Zhang, Q., Lu, S., Li, T., Yu, L., Zhang, Y., Zeng, H., Qian, X., Bi, J. and Lin, Y. (2019). ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. <em>Journal of Experimental &amp; Clinical Cancer Research</em>, 38<strong>(1)</strong>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8c400c37317f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Dexamethasone: Will This Finally Be The One to Fight COVID-19?]]></title>
            <link>https://medium.com/@stevensankey/dexamethasone-will-this-finally-be-the-one-to-fight-covid-19-c9a5a585412b?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/c9a5a585412b</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[dexamethasone]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[pandemic]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Tue, 23 Jun 2020 16:38:59 GMT</pubDate>
            <atom:updated>2020-06-23T16:38:59.693Z</atom:updated>
            <content:encoded><![CDATA[<p><em>A new study has found dexamethasone to be an effective treatment for the worst hit sufferers of COVID-19 but what is it and does it work?</em></p><figure><img alt="Random generic packets of pills messily strewn across an unseen surface." src="https://cdn-images-1.medium.com/max/1024/1*ArzuUGygFOiT72ePMGeD5g.jpeg" /></figure><p>Have you heard of this game-changing drug? Are you sick of hearing the words “game-changing?” Of course you have, and of course you are, because today is a day that ends with ‘day’.</p><p>Please excuse my dour cynicism but it seems every day we hear about an ‘exciting’ drug already in use for other ailments which can be co-opted for COVID-19 treatments. Then, about a month later, we hear that the drug is actually useless, or worse may actually exacerbate the symptoms à la the <a href="https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19">hydroxychloroquine</a> fiasco after being touted by the President of the United States himself, Donald J. Trump, multiple times on national television and social media.</p><p>It’s almost like there should be some kind of rigorous scientific testing that should be administered before politicians start promoting drugs with pseudoscience. Oh wait… there is.</p><p>Like many of the drugs currently in circulation which are being tested for their effectiveness against COVID-19, <a href="http://chemocare.com/chemotherapy/drug-info/dexamethasone.aspx">dexamethasone</a> is a steroid which temporarily reduces the body’s immune system response, and in turn reduces inflammation.</p><p>It is the overreaction of the body’s immune system response — known as a <a href="https://medium.com/@stevensankey/but-what-actually-is-coronavirus-5ccdad495f12">hyperactive response</a> — that is believed to cause the worst of the COVID-19 symptoms. This is where our immune system stops specifically targeting and destroying cells infected with the virus and instead targets everything in its path. This can lead to pneumonia, organ failure, and ultimately death.</p><p>Remember that rigorous scientific testing I mentioned earlier? Well, dexamethasone has actually shown promising results from a scientific trial including over six thousand participants (now that’s a good sample size!)</p><p>The short of it is, 2104 randomised patients were treated with dexamethasone and their mortality rates were compared with 4321 randomised patients who received the usual medical care alone.</p><p><a href="https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19">The results showed that dexamethasone</a> reduced mortality in patients on ventilators by up to one third, and up to one fifth in patients needing oxygen. No benefit was found for those patients not in need of respiratory support.</p><p>If patients had been treated with dexamethasone from the beginning of the outbreak, in the U.K. alone up to 5,000 deaths could have been prevented. At the time of writing, the death toll in the U.K. is around 43,000. In the world, over 475,000 deaths have been recorded so far.</p><p>Allow me to shrug off my fervent cynicism for a moment and explain that this time, this is actually exciting news. A solid study, with a large sample size, producing these results <em>is</em> cause for celebration. And what’s more, since dexamethasone was created in 1957, it is out of patent which means companies around the world can make this drug on the cheap.</p><p>The U.K. government has confirmed that it has enough dexamethasone stockpiled to treat around 200,000 patients.</p><p>Of course, however, this is only a stop-gap in the fight against this pandemic. Dexamethasone is a weapon against COVID-19 that has the potential to save thousands of lives but thousands more are still in peril from a virus that has no real cure yet. Hopefully, dexamethasone will not be the last drug to show promise in helping to save lives, but it is just a stall until a working vaccine can be developed and manufactured for the entire world.</p><p>This is a triumph but let us not forget that there is still a deadly virus out there, and it’s killing people every day. We must continue to be vigilant and do whatever we can to help prevent the spread of infections. It is up to all of us to stay safe out there.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c9a5a585412b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Studies Show 50–80% of Coronavirus Cases Show No Symptoms But How True is This?]]></title>
            <link>https://medium.com/@stevensankey/studies-show-50-80-of-coronavirus-cases-show-no-symptoms-but-how-true-is-this-aabe0979bd05?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/aabe0979bd05</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[asymptomatic]]></category>
            <category><![CDATA[pandemic]]></category>
            <category><![CDATA[medium]]></category>
            <category><![CDATA[coronavirus]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Wed, 08 Apr 2020 20:53:24 GMT</pubDate>
            <atom:updated>2020-04-09T15:07:00.723Z</atom:updated>
            <content:encoded><![CDATA[<h3>Studies Show 50%–80% of Coronavirus Cases Show No Symptoms But How True is This?</h3><p><em>What do China, the Diamond Princess, and Iceland have in common? They have the media in a frenzy over COVID-19.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*r1QlnNZBTBTj82Wexu9V8w.jpeg" /></figure><p>At the time of writing, the novel coronavirus, SARS-CoV-2, <a href="https://www.worldometers.info/coronavirus/">confirmed cases</a> approach 1.5 million people worldwide, with over 87,000 deaths. With cases and deaths on the rise in places like the United Kingdom and the United States, those numbers are sure to keep rising for the near future.</p><p>Anxiety is running high throughout the world, around a third of which is under some sort of lockdown. With more and more people becoming infected and critically ill, including the U.K. Prime Minister Boris Johnson, criticism over a lack of testing is widespread across the globe.</p><p>At the moment, conventional testing only determines if you are currently infected with SARS-CoV-2, it does not test to see if you’ve had it previously. So, the question everybody is asking right now is how many people are asymptomatic? That is, how many people have had the virus without showing any symptoms at all of the disease, COVID-19.</p><p>This is an extremely important question, not just to ease the minds of many left in limbo after self-isolating but without being tested, left to wonder if they really had the virus or just the seasonal flu which shares many of the same symptoms. It is also important because the prevailing theory is that asymptomatic cases are still infectious. Many scientists believe that the rapid transmission of the virus has been in part due to asymptomatic cases unwittingly infecting others.</p><p>There have been multiple studies already released which suggest high levels of cases which don’t develop symptoms, and the media has been touting figures between fifty and eighty per cent of cases being asymptomatic. If this is true then it could suggest that many, many more people have had the virus and therefore are now suspected to be immune to the disease it causes, COVID-19, which could potentially see life as we once knew it return much sooner than previously expected.</p><p>But how true are these extraordinary statistics?</p><p>Call me a cynic, but these felt a little too good to be true, so I decided to once again dig deep into the research of the three most prevalent stories. Here’s what I found.</p><h3>The Diamond Princess</h3><p>At the beginning of February news broke that a Princess Cruises ship, the Diamond, was being quarantined whilst docked at Yokohama, Japan, after a passenger had tested positive for SARS-CoV-2.</p><p>Recently, a study has once again been trotted out across the U.K. media, purportedly stating that fifty per cent of novel coronavirus cases could be asymptomatic.</p><p>The study by <a href="https://eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180">Mizumoto et al.</a>, was carried out on the some 3,063 passengers and crew between February 5 and February 20, 2020, of which 634 tested positive for SARS-CoV-2. Of those 634 confirmed cases, it is true that 320 (50.5%) of those were registered as asymptomatic within the parameters of the study. On the face of it, it would seem the media were telling the truth.</p><p>However, it was no dramatic flair on my part to add “within the parameters of the study” as this makes all the difference when getting into the gritty details.</p><p>The study states that the asymptomatic cases were characterised as, “both true asymptomatic infections and cases who had not yet developed symptoms at the time of data collection but became symptomatic later”. This is something called <a href="https://www.jstor.org/stable/pdf/2529941.pdf?seq=1">right censored</a> data.</p><p>Further into the study it explains that, by using established complex models, the estimated rate of true asymptomatic cases (those which never developed symptoms even after the the time of data collection) was 0.35. Meaning that only 35% of those 50.5% deemed asymptomatic were estimated to be true asymptomatic. This brings the actual estimate of true asymptomatic cases down from the media-touted 50.5%, to a more modest 17.9%. The other estimated 65% of asymptomatic cases merely developed symptoms unusually late.</p><p>This study was also not a random sample of the population and therefore extrapolating conclusions for the entire world population, such as the media tend to do, is highly discouraged. The study itself also states this. Most of the passengers were sixty years of age or over and therefore are not a representative sample of the wider world population. Even if these statistics could be applied to the wider world population, the study still only estimates that around 18% of all cases could be asymptomatic, a far cry from the 50% the media headlines would have us believe.</p><h3>The Icelandic Study</h3><p>Iceland is pretty small. It has a population of just over 360,000 and has hit the ground running on testing all of its citizens for SARS-CoV-2, not just those showing symptoms. These are all facts. It is also a fact that DeCODE, a subsidiary of Amgen, have carried out much of the testing and that Dr. Kári Stefánsson, the company’s founder, <a href="https://edition.cnn.com/2020/04/01/europe/iceland-testing-coronavirus-intl/index.html">told CNN in April</a> that so far out of around 9,000 self-selected people tested, 50% of all confirmed cases have been asymptomatic.</p><p>Who can argue with those numbers?</p><p>Well, while the sample size seems more than large enough to produce reliable data, the reality is that less than 1% of those tests tested positive. Meaning that the real sample size is around 90 confirmed cases, in which around 45 cases were asymptomatic. Suddenly, those figures don’t seem that big or reliable.</p><p>When trying to determine the rate of asymptomatic cases, the two figures which truly matter are the confirmed cases and those confirmed cases which are asymptomatic. In this case, 99% of the data, which have tested negative, is disregarded.</p><p>Sadly, although an exciting headline, a sample size of around 90 confirmed cases is just far too small to draw any conclusions from, and certainly cannot be scaled up to the whole population.</p><h3>The China 78%</h3><p>As the outbreak of the novel coronavirus originated in Wuhan City of the Hubei Province in China, much of the initial data and research is naturally coming out of Chinese labs and scientists.</p><p>In the past week, you may have already heard something along the lines of ‘four out of five cases are asymptomatic’ in regards to the SARS-CoV-2 pandemic. This would be because an article was published in the <a href="https://www.bmj.com/content/369/bmj.m1375">British Medical Journal on April 2</a>, touting the fact that a whopping 78% of people who tested positive for SARS-CoV-2 in China on April 1 were asymptomatic for the disease, COVID-19.</p><p>However, a small rummage through the sparse facts revealed that only 166 people tested positive within this 24 hour period, 130 of whom were asymptomatic. No other details were present.</p><p>The article does not describe how these people were chosen for testing, when they were likely infected, or how they determine someone is asymptomatic. Furthermore, this is data collected over 24 hours about a disease which takes an average of five days to show symptoms. Meaning, those 130 asymptomatic cases may not remain asymptomatic, they merely weren’t showing symptoms at the time of testing. We come back to right censoring again, except on a much shorter time scale than the <a href="https://eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180">Diamond Princess study</a>.</p><p>Ultimately, this very small sample size and extremely limited time scale makes this data almost meaningless. Certainly not enough to base any kind of assumptions off, nor reliable enough to generalise as is suggested in the article itself. Any conclusions derived from this data are mere speculation.</p><h3>So What Does This Mean?</h3><p>This means, for now at least, we just don’t know the rate of asymptomatic cases across a population, nor do we have reliable enough data to extrapolate even an educated estimate.</p><p>As this pandemic continues to spread, countries across the world are struggling to keep up with testing targets. It could be that, before we can make any reliable suggestions on asymptomatic case rates, we will need to wait for the long anticipated <a href="https://medium.com/@stevensankey/what-is-an-antibody-test-and-how-does-it-test-for-coronavirus-32413cc1c5dc">antibody tests</a> to be rolled out en masse.</p><p>Ultimately, much of this comes down to media sensationalization as they vie for those coveted clicks, as 50% or even 80% sounds much more exciting than just 18% or ‘we just don’t know’ in headlines.</p><p>As for the experts who have weighed in on these studies in the media, unfortunately even scientists aren’t immune to being mistaken, misled, or overly optimistic about such data. We are, afterall, human.</p><p>It is natural that in these dark times people would search for the smallest of light. The real silver lining here is that the media and, more importantly, the public are listening to experts and scientists. And as I wrote in a <a href="https://medium.com/@stevensankey/opinion-what-the-coronavirus-pandemic-can-teach-us-about-listening-to-scientists-9acd5ca582f0">previous article</a>, it’s not about believing everything you hear or read, it’s about listening to and at least considering the science which is important, and this seems to be something people are doing more and more lately.</p><h3>Further Reading</h3><p>Day, M., 2020. Covid-19: four fifths of cases are asymptomatic, China figures indicate. <em>BMJ</em>, p.m1375.</p><p>Mizumoto, K., Kagaya, K., Zarebski, A. and Chowell, G., 2020. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. <em>Eurosurveillance</em>, 25<strong>(10)</strong>.</p><p>Sankey, S. (2020). <em>What is an Antibody Test and How Does it Test for Coronavirus?</em>. [online] Available at: <a href="https://medium.com/@stevensankey/what-is-an-antibody-test-and-how-does-it-test-for-coronavirus-32413cc1c5dc">https://medium.com/@stevensankey/what-is-an-antibody-test-and-how-does-it-test-for-coronavirus-32413cc1c5dc</a>.</p><p>Tara John, C. (2020). <em>Iceland lab’s testing suggests 50% of coronavirus cases have no symptoms</em>. [online] CNN. Available at: <a href="https://edition.cnn.com/2020/04/01/europe/iceland-testing-coronavirus-intl/index.html">https://edition.cnn.com/2020/04/01/europe/iceland-testing-coronavirus-intl/index.html</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aabe0979bd05" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Opinion | What The Coronavirus Pandemic Can Teach Us About Listening to Scientists]]></title>
            <link>https://medium.com/@stevensankey/opinion-what-the-coronavirus-pandemic-can-teach-us-about-listening-to-scientists-9acd5ca582f0?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/9acd5ca582f0</guid>
            <category><![CDATA[opinion]]></category>
            <category><![CDATA[politics]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Mon, 06 Apr 2020 18:31:40 GMT</pubDate>
            <atom:updated>2020-04-11T11:18:51.085Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/620/1*EhYj8rV3q6YqWgXKnFRRvg.jpeg" /><figcaption>(Photograph: Leon Neal/Pool via Reuters)</figcaption></figure><p>As the confirmed novel coronavirus, SARS-CoV-2, cases surpass one million worldwide, and deaths rise to over fifty thousand souls, one small silver lining in these dark times is that people are finally taking notice of science and scientists.</p><p>2019 seems so distant now, so long ago, so pre-COVID-19. But if we cast our minds back to that year we may just be able to remember that it was also a tumultuous year in itself, albeit for what seems like much more trivial reasons, now. Brexit. Megxit. Impeachment of President Trump. How simple times were way back when.</p><p>One stark difference between then and now is that, as a scientist, it felt like politicians and, more importantly, the general public just weren’t listening to scientists at all, and were sceptical, at best, of science itself.</p><p>Ever since the mass debates around the United Kingdom European Union membership referendum of 2016, there has been an audible scoff from the general public in the U.K. whenever someone dares to utter the word “expert”.</p><p>“Well, what do they know?” I heard from many-a-rebutter. (A lot, is the answer to that question. It’s kind of their whole thing).</p><p>“They are just trying to scare us!” Is another I frequently heard in a vain attempt to rationalise the severity of any given situation. But, sadly, no, experts don’t usually go in for fear mongering tactics. If the facts sound scary, it’s probably because they are. Take heed.</p><p>“They are being paid to say those things”, is another common phrase spat out in defiance of the experts, and it’s a pretty huge accusation for academics. Most experts have the professional and moral integrity to tell you the facts, from their data. There are, of course, the small few who may allow their political or personal biases to cloud their judgement. However, if most of the experts are saying the same things, it’s worth taking note.</p><p>Our American cousins are also currently dealing with their own rejection of established science under the regime of one Donald J. Trump and his anti-science henchmen including, but not limited to, Vice President Mike Pence and vast swathes of the Republican Party. From Senators attempting to seriously pass legislation which would force doctors to perform surgeries that are medically impossible, to a concerted effort to suppress access to safe, legal abortions. None of which is based on real, established science, but instead wholly based in ideology and dangerous levels of misinformation.</p><p>But now, due to the very immediate and very serious threat of the novel coronavirus, politicians are being forced to finally listen to their scientific advisers, and the scientific community as a whole. Furthermore, policy and law is being ratified at breakneck pace, all in line with how science says we should proceed. Science and health advisers are even on television and in the media every day making announcements, updates, and giving advice. The whole world has finally turned its collective heads to the oft scoffed at and forgotten scientists and asking, “What do we do now?” and, “When will a vaccine be ready?”</p><p>When this whole pandemic epoch is finally over, it’s worth the public and politicians remembering who they turned to when things became serious. When things became deadly. They turned not to propaganda, and not to their chequebooks; they turned to science and did what was necessary, when it was necessary. Something the whole world is guilty of not doing for another contemporary crisis underway: climate change.</p><p>For <a href="https://www.scientificamerican.com/article/exxon-knew-about-climate-change-almost-40-years-ago/">over forty years</a> businesses like Exxon and Shell have known the science behind the impending effects of fossil fuel CO2 emissions and the looming threat of serious and irreparable climate change. In fact, there have been many scientists dating <a href="https://www.nationalgeographic.com/magazine/2018/07/embark-essay-climate-change-pollution-revkin/">as far back as 1896</a> who predicted the climate crisis we are facing at this very moment.</p><p>For over a century we had some idea this was coming. For over three decades the public and politicians have been made very aware of the imminent threat of climate change. And yet we all sat back and did nothing but scoff at the scientists who were screaming at the masses of businesses, politicians, and a public who refused to take it seriously; who refused to believe and act on the science.</p><p>And the scoffs are still audible to this very day.</p><p>Unfortunately, this attitude doesn’t end with climate change, there has been a huge rejection of science across many fronts in recent times, such as vaccinations, genetically engineered (GE) foods, traditional medicines, and much, much more.</p><p>It is my personal hope that after the dust settles on this devastating pandemic, that people begin to trust in science and in scientists again. That people won’t scoff when they hear the word “expert” but will in fact sit up and take notice. It’s not about obeying blindly or believing everything you read, but listening and consideration are hugely important. Many scientists don’t agree with one another but they do always listen and always consider the science.</p><p>It is my hope that politicians continue to listen and act on the science brought to them by their advisers and the scientific community as a whole. And if they stop, that the public will remind them of how we got through the COVID-19 pandemic. By listening to the scientists — the experts — and by basing our decisions and policy on the science.</p><p>It is my hope that once a vaccine is ready to be rolled out the masses, that people trust in vaccinations again and are reminded of the immense power of vaccinations to save millions of lives every year. And when people begin to forget this, others remind them.</p><p>Maybe, just maybe, people will begin to recycle more. Be more fuel efficient, and take more public transport. Push for more sustainable energy sources, and turn their lights off when they leave a room.</p><p>Maybe, just maybe, businesses will ramp up their efforts to become greener and safer for the environment. Maybe most of those who are working from home right now will be allowed to continue to do so, to help remove the need for so many vehicles on the roads and the need for the fuel they use.</p><p>And maybe — just maybe — our political leaders will continue to listen to scientists and create policies that protect the environment and help stave off the worst of climate change. To support cheap and reliable public transport to reduce the amount of vehicles on the roads. To push policy that makes cleaner energy sources the primary source of power in the country as a whole. To reconsider their resistance to GE foods, which could save hundreds of thousands of lives every year. And so, so much more.</p><p>There are a lot of ‘maybes’ in those paragraphs but I have hope that we, as a society, will push to make those maybes a reality, and come out of these dark times much more informed and much more open to science challenging our preconceptions and ultimately informing our personal opinions and beliefs.</p><p>Science isn’t good nor evil. Science isn’t political or financially inclined. Science is merely information. It is up to us whether we use that information or ignore it. Let’s not live in ignorance any longer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9acd5ca582f0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What is an Antibody Test and How Does it Test for Coronavirus?]]></title>
            <link>https://medium.com/@stevensankey/what-is-an-antibody-test-and-how-does-it-test-for-coronavirus-32413cc1c5dc?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/32413cc1c5dc</guid>
            <category><![CDATA[test]]></category>
            <category><![CDATA[antibody]]></category>
            <category><![CDATA[serology]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Sun, 22 Mar 2020 17:46:19 GMT</pubDate>
            <atom:updated>2020-03-22T17:46:19.060Z</atom:updated>
            <content:encoded><![CDATA[<p><em>How can we know if someone has already contracted the novel coronavirus, especially if many are mild-to-asymptomatic? New antibody tests could have the answers.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5anmz-2AIaBSRXS7PhwGzw.jpeg" /></figure><p>Anxiety around the <a href="https://medium.com/@stevensankey/but-what-actually-is-coronavirus-5ccdad495f12">novel coronavirus</a>, SARS-CoV-2, and the disease it causes, COVID-19, is on the rise as governments all over the world start locking down people, businesses and, in some cases, entire continents. The real severity of the situation is finally starting to sink and I, for one, am certainly feeling the worry creep in.</p><p>Much of this anxiety stems from the fact that people just don’t know if they have the virus or not at any given time. With the long incubation time of an average of five days, it could be almost a week before you know you’ve caught it and it’s contagious before symptoms even show. COVID-19 symptoms have a wide range of severity — essentially, from nothing to severe— and therefore leave many not even knowing if they’ve already had the disease and have been one of the lucky few to be asymptomatic (show no symptoms of the disease). Wouldn’t it be such a relief to know you’ve already had COVID-19 and therefore are no longer in danger, or no longer a danger to others? It sure would be for me.</p><p>However, a small light in these dark times is the recent news that a new antibody test has been developed in countries around the world that can test not if you currently have the novel coronavirus (we already have those tests) but if you’ve <em>already had it</em>. However, this news left many heads a cocked, asking “What even is an antibody test?”</p><h4>Serology, Antibodies, and the Immune System</h4><p>Serology is a term that has been injected into much of the media surrounding these new antibody tests. It means the study or examination of blood serum, usually in regards to the immune system. Which is exactly where we would want to look for signs of a previous SARS-CoV-2 infection.</p><figure><img alt="A representation of a typical antibody. The antigen binding site is specific to the target antigen." src="https://cdn-images-1.medium.com/max/400/1*-RPWb30O68dHPtCuZHSt8A.png" /><figcaption>A representation of a typical antibody. The antigen binding site is specific to the target antigen.</figcaption></figure><p>When we are infected by a virus (or pathogenic bacteria), our immune system responds by producing antibodies from B cells, a type of white blood cell. These antibodies, which are large Y-shaped proteins, are designed to specifically bind to said infector. Antibodies bind to antigens, and are specific to the antigen. Antigens are a type of molecule presented on the surface of cells that enable the immune system to recognise native and non-native cells. For example, this is why if you have blood type A, you cannot receive a transfusion from someone with blood type B, as these refer to the antigens present on the red blood cells. In a person with blood type A, type B blood cells will be targeted by their immune system. This is also why blood type O-negative is a universal donor, as it has no antigens for the immune system to react to.</p><h4>SARS-CoV-2 Antigen and Antibodies</h4><p>The antigen on SARS-CoV-2 virions (virus particles) are the peplomers (also called spike proteins) on the outside of the virion capsid. These peplomers allow the virus to bind, fuse, and invade some of our cells. Research suggests that SARS-CoV-2, like SARS-CoV, <a href="https://science.sciencemag.org/content/early/2020/03/03/science.abb2762.full?fbclid=IwAR1AFKWaY_JV0hdyT3vDoxl3V49GUsYbQ0lnUE16wyfDxx_5U2m067iDJRI">binds to ACE2 receptors</a> expressed on lung, heart, kidney and intestinal cells.</p><figure><img alt="A 3D representation of a typical coronavirus virion, with its peplomers in red and capsid in grey" src="https://cdn-images-1.medium.com/max/1024/1*mR7uT2YkkWKdSkji8sDXvw.png" /><figcaption>A 3D representation of a typical coronavirus virion, with its peplomers in red and capsid in grey (image: <a href="https://phil.cdc.gov/">PHIL</a>).</figcaption></figure><p>Once a virion has invaded a cell it then uses the cell’s own molecular machinery to replicate and release more virions. Within this replication process, some of the virus antigen is presented on our own cells, which can be identified by our immune system.</p><p>By binding to these antigens, our antibodies can help prevent the virus from binding and infecting our cells, restricting its ability to replicate and spread. Antibodies also mark virions, and our own infected cells presenting the virus antigen, for destruction by the immune system. This is the system by which our bodies fight these infections, by isolating virions and locking down infected cells. In a similar sense to how we humans are self-isolating infected people and locking down heavily infected communities and countries.</p><p>After the virus has been eradicated by our immune system, a small amount of these virus-specific antibodies remain in the blood. These aid in immediately suppressing a second infection. The presence of these antibodies are a kind of memory as to what pathogens we have been exposed to. Therefore, if a test shows the presence of SARS-CoV-2 antibodies, then the patient has previously been infected.</p><h4>How Does the Antibody Test Work?</h4><p>The current SARS-CoV-2 antibody tests — known as serology tests — in production all rely on <a href="https://www.thermofisher.com/uk/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-elisa.html">the ELISA</a> (enzyme-linked immunosorbent assay) system.</p><p>In short, an ELISA test relies on antigen-antibody binding. It is most likely that an indirect or sandwich ELISA will be used for such tests, as were used for the <a href="https://link.springer.com/article/10.1007/s10096-005-1378-7">SARS-CoV outbreak of 2002–03</a>.</p><p><a href="https://www.thermofisher.com/uk/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-elisa.html">An indirect ELISA test</a> uses a plate that contains immobilised antigen. In this case, that antigen would be the SARS-CoV-2 peplomer. If a patient sample contains the SARS-CoV-2 antibodies, these will bind to the immobilised antigen. If present, the SARS-CoV-2 antibodies — now bound to the immobilized antigen — will recruit a secondary antibody which is bound to a reporter molecule (known as a secondary antibody conjugate). If positive for the SARS-CoV-2 antibody, the reporter molecule on the secondary antibody conjugate will initiate a visible colour change on the plate.</p><p>A sandwich ELISA test is much the same as an indirect ELISA test, except the antigen is first bound to an immobilised antibody on the surface of the plate.</p><figure><img alt="A representation of indirect and sandwich ELISA tests resulting in a visible colour change to indicate a positive result." src="https://cdn-images-1.medium.com/max/392/1*cRtvcRMdktubij82yQi-Cg.png" /><figcaption>A representation of indirect and sandwich ELISA tests resulting in a visible colour change to indicate a positive SARS-CoV-2 antibody result (edited from <a href="https://www.bosterbio.com/protocol-and-troubleshooting/elisa-principle">BosterBio</a>).</figcaption></figure><p>This all may sound confusing but we are all very aware of this process perhaps without even knowing it, as ELISA is the method used in home pregnancy tests which use coloured bands to indicate a positive or negative result depending on the presence or absence of HCG (human chorionic gonadotropin) hormone in the sample (usually urine), respectively.</p><p>The SARS-CoV-2 antibody tests test for IgG (Immunoglobulin G) and IgM (Immunoglobulin M) antibodies. IgG antibodies are those Y-shaped antibodies we are more used to seeing depicted, and are the most abundant. IgM antibodies are those produced first by the immune system in response to an infection and only remain in the blood for a few weeks. The presence of IgG antibodies indicates a previous infection. The presence of both IgM and IgG antibodies indicate a very recent infection.</p><h4>How Will an Antibody Test Help?</h4><p>Being able to reliably confirm if a person has had COVID-19, especially if symptomless, would be a great help in more accurately tracking the spread of the virus and calculating how many cases are truly symptomless, along with allowing a more accurate mortality rate to be calculated. It could also be expected to enable people to safely socialise and go back to work, as well as not having to self-isolate again. This could see a modicum of normality return to many peoples’ lives.</p><p>On the other hand, finding large populations which have not yet been infected with SARS-CoV-2 would aid governments and healthcare in focussing on areas with high likelihood of an impending outbreak.</p><p>On a more individual note, knowing for sure if you have personally had, or not had, COVID-19 would go a long way to relieving some of the stress and anxiety that is palpable in communities across the world right now.</p><h4>Further Reading</h4><p>Chen, S., Lu, D., Zhang, M., Che, J., Yin, Z., Zhang, S., Zhang, W., Bo, X., Ding, Y. and Wang, S., 2005. Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum. <em>European Journal of Clinical Microbiology &amp; Infectious Diseases</em>, 24<strong>(8)</strong>, 549–553.</p><p>Sciences, L., Biology, P., Center, P., Library, P., Methods, P. and ELISA, O. (2020). Overview of ELISA | Thermo Fisher Scientific — UK. [online] Thermofisher.com. Available at: <a href="https://www.thermofisher.com/uk/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-elisa.html">https://www.thermofisher.com/uk/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-elisa.html</a></p><p>Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y. and Zhou, Q., 2020. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. <em>Science</em>, p.eabb2762.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=32413cc1c5dc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What is Herd Immunity?]]></title>
            <link>https://medium.com/@stevensankey/what-is-herd-immunity-ffe139d3e3f8?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/ffe139d3e3f8</guid>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[pandemic]]></category>
            <category><![CDATA[uk-politics]]></category>
            <category><![CDATA[herd-immunity]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Sat, 14 Mar 2020 00:29:49 GMT</pubDate>
            <atom:updated>2020-03-14T00:32:38.268Z</atom:updated>
            <content:encoded><![CDATA[<p><em>In the wake of the coronavirus pandemic the U.K. has strayed from the pack and into the herd.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*w-hXo7rAzDPJCfMCCpTfHQ.jpeg" /></figure><p>On Thursday it was reported that the United Kingdom government has moved out of the containment phase and into the delay phase of their four stage plan to attempt to tackle the pandemic novel coronavirus disease, COVID-19.</p><p>It was expected that the U.K. would follow in the footsteps of its continental neighbours and begin to close schools, colleges, and banning mass gatherings to help prevent the spread of the virus. However, this was not the case.</p><p>The U.K. Prime Minister Boris Johnson announced Thursday that the country will not be undertaking similar action to that of affected countries such as Italy, France, Germany, Spain and the Republic of Ireland. At least, not for now. Instead, it seems the kingdom is hunkering down for the long haul.</p><p>The U.K. government has said that the unexpected move is based purely in science, and that since the infection may not peak for another 14 weeks, it is unlikely the same extraordinary social distancing measures that other countries have adopted could be kept up. In short, it’s just not feasible to lock the country down for three months, both socially and economically.</p><p>And then came that term: herd immunity.</p><h4>Herd Immunity</h4><p>The U.K. government believes that the novel coronavirus (SARS-CoV-2), which causes the disease COVID-19, isn’t going anywhere for the foreseeable future and, like seasonal flu, could become a yearly menace. This indefinite outbreak has caused the government to switch tactics and opt for a herd immunity approach.</p><p><a href="https://academic.oup.com/cid/article/52/7/911/299077">Herd immunity</a> is not a new concept, in fact it was a homegrown Briton by the name of Sir William Heaton Hamer who came up with the <a href="https://www.sciencedirect.com/science/article/pii/S0140673601801872">theory in 1906</a>, although the actual term wasn’t coined until 1923.</p><p>The concept of herd immunity is a relatively simple one. If enough people in a community or population have an immunity to a communicable disease, those with no immunity will be protected by proxy.</p><p>So for example, if there is an isolated community of 20 people and 19 of those are inoculated against measles, the one person who isn’t immune won’t be infected with measles due to the disease not being able to spread from the immune 19. This is the very basics of the herd immunity theory.</p><p>Of course, communities are not isolated and there are many more factors that can contribute to the spread of a disease. Also, without a vaccine for at least twelve months (and likely longer) immunity comes at a cost: you actually have to get sick and let your own immune system do all the work (see: <a href="https://medium.com/@stevensankey/but-what-actually-is-coronavirus-5ccdad495f12">But What Actually is Coronavirus?!</a>).</p><p>Due to the expected long term nature of COVID-19, the U.K. government has opted to accept a widespread infection as all but inevitable now, and have redirected their efforts into controlling the spread of the disease as not to overwhelm the National Health Service (NHS). The idea being that if the majority of the healthy population catch the virus and develop their own immunity to it, the most vulnerable and at risk in the population will be much more protected by proxy, as it will now be much more difficult for the virus to spread. Those who are immune to COVID-19, even if reintroduced to the virus, do not become infectious and therefore the virus cannot spread. Sir Patrick Vallance, the government’s chief scientific adviser, believes that 60 per cent of the population would need to develop an immunity to COVID-19 for herd immunity to take effect.</p><p><a href="https://academic.oup.com/epirev/article-abstract/15/2/265/440430?redirectedFrom=fulltext">Herd immunity</a> has been used, successfully, in the past in the complete global eradication of smallpox and the eradication of measles in many countries. It has also been observed that when vaccination uptakes fall low, a disease can resurge in a population. This was documented in the <a href="http://www.wales.nhs.uk/sites3/page.cfm?orgId=457&amp;pid=25444">2012–2013 measles outbreak in Wales</a>, where due to historically low MMR (measles, mumps, and rubella) vaccinations <a href="http://www.euro.who.int/__data/assets/pdf_file/0003/191910/EpiBrief_2_2013_FINAL.pdf">at least 1400 people</a> were reported to have the disease over six months.</p><p>There are vulnerable people in communities who today already rely on herd immunity to reduce their chances of infections, which could be potentially deadly. These being immunocompromised individuals, newborn babies, the elderly, <a href="https://vk.ovg.ox.ac.uk/vk/herd-immunity">and more</a>.</p><h4>Divided Opinions</h4><p>The efficacy of the herd immunity strategy and the lack of social distancing measures undertaken by the U.K. government has a somewhat divided opinion within the medical community.</p><p>Some, such as Richard Horton, editor-in-chief of the journal The Lancet, have expressed their concerns that without more extreme social distancing measures the U.K. could soon find itself in the same situation as Italy is in now.</p><p>Others, however, have come to the defense of this strategy, such as <a href="https://edition.cnn.com/2020/03/13/uk/uk-coronavirus-response-boris-johnson-intl-gbr/index.html">Dr Clare Wenham who told CNN</a> that “Johnson is listening to the current evidence that’s out there” and hasn’t “bowed to pressure” unlike other political leaders. Keith Neal, emeritus professor in the epidemiology of infectious diseases at the University of Nottingham, also said “the plans are sensible” and remarked that calls for more action are easy but lack evidence to make any decisions.</p><p>As the world reacts to combat the spread and toll of the novel coronavirus, it seems that the U.K. is taking its own sage advice to keep calm and carry on.</p><h4>Further Reading</h4><p>Fine, P., 1993. Herd Immunity: History, Theory, Practice. <em>Epidemiologic Reviews</em>, 15<strong>(2)</strong>, 265–302.</p><p>Fine, P., Eames, K. and Heymann, D., 2011. “Herd Immunity”: A Rough Guide. <em>Clinical Infectious Diseases</em>, 52(7), pp.911–916.</p><p>Vk.ovg.ox.ac.uk. (2020). Herd immunity (Herd protection) | Vaccine Knowledge. [online] Available at: <a href="https://vk.ovg.ox.ac.uk/vk/herd-immunity">https://vk.ovg.ox.ac.uk/vk/herd-immunity</a> [Accessed 14 Mar. 2020].</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ffe139d3e3f8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[But What Actually is Coronavirus?!]]></title>
            <link>https://medium.com/@stevensankey/but-what-actually-is-coronavirus-5ccdad495f12?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/5ccdad495f12</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[sars-cov2]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[virus]]></category>
            <category><![CDATA[disease]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Sun, 08 Mar 2020 17:15:04 GMT</pubDate>
            <atom:updated>2020-04-07T09:46:52.204Z</atom:updated>
            <content:encoded><![CDATA[<h3>But What Actually is Coronavirus?</h3><p><em>Infection, replication, destruction. What actually is coronavirus and what does it do?</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Iw3S-4pKQ7GtliUxJRe_Lw.jpeg" /></figure><p>You’ve all heard its name, you all know what’s happening across the world right now, and we are all acutely aware of the danger. So, I’ll spare us all and won’t retread that old ground.</p><p>It seems like every day this deadly new virus gains a foothold in a new country and spreads quickly. It’s scary. It scares me. If it scares you too then I truly empathise. But when something scares me I find the more I learn about it, the less it scares me.</p><p>What really rattles people isn’t the word “virus”, we’re used to them, it’s the word “new”. We fear what we don’t know and what we don’t understand. And, if you’re like me, the wishy-washy explanations of the coronavirus you find in mainstream news articles just do not soothe my frayed nerves enough.</p><p>So, I went into full research mode and this is what I found.</p><h4>The Name</h4><p>Firstly, it has nothing to do with beer, let’s just get that out of the way with, although they do share the same origin: Latin. Corona is the Latin for ‘crown’, hence the beer’s logo being a crown. It’s also where The Sun’s corona received its name (technically from the original Ancient Greek ‘ κορώνη’, which the Latin is a derivation of), the aura (or crown) of plasma which surrounds our native star. And this is also where the ‘corona’ in the coronavirus derives its name, as the club-like protrusions (peplomers) on the virus’ main body (capsid) give an appearance somewhat similar to The Sun’s corona when viewed through electron microscopy.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vHFXS7hPLqRnUgylk4S1Mg.png" /><figcaption>A 3D representation of a typical coronavirus virion, with its peplomers in red and capsid in grey (image: <a href="https://phil.cdc.gov/">PHIL</a>).</figcaption></figure><h4>The Basics</h4><p>The name ‘coronavirus’ isn’t actually specific to any one virus, but all viruses from the <em>Coronavirinae</em> virus subfamily, from the <em>Coronaviridae </em>virus family. This subfamily also contains the infamous SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome Coronavirus) viruses, as well as our perennial tormentor, the common cold (which in itself comprises of over 200 known viral strains).</p><p>The particular coronavirus causing havoc at the moment is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is genetically related to SARS-CoV, which caused a global epidemic in 2002–2003. SARS-CoV-2 results in COVID-19 (no please, give it a more terrifying and James-Bond-villain-weapon-like name), which actually translates to COronaVIrus Disease-2019.</p><p>COVID-19 can present <a href="https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html">symptoms</a> such as fever, cough, and shortness of breath. These symptoms can range from <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2001737">minimally symptomatic</a> to acute and life-threatening. This is something we are all intensely aware of currently but how does SARS-CoV-2 actually infect us, makes us sick, and spread?</p><h4>How SARS-CoV-2 Works</h4><p>SARS-CoV-2 acts like most other coronaviruses, in the sense that it invades our cells and uses our own cellular machinery to replicate itself. It essentially uses our cells as virus factories.</p><p>OK, let’s take a step back and briefly discuss some of our usual cellular machinery. Much of what human cells are made up of are proteins. We create these proteins ourselves within our cells, using genetic blueprints we call genes. Our genes are basically just long stretches of our DNA.</p><p>The DNA which encodes a gene is essentially ‘unzipped’ and <em>transcribed </em>into something called messenger-RNA (mRNA). mRNA is a single-stranded molecule which is similar to DNA (but DNA is double-stranded), created specifically to make a particular protein. This mRNA is then <em>translated</em> into a string of amino acids, which eventually fold up into said protein.</p><p>Within the capsid of a SARS-CoV-2 virion (a single virus particle) lies its own <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25681">genetic material</a>; a single-stranded positive-sense RNA with a 5&#39;-cap and 3&#39;-poly-A tail. Now, that’s a bit technical even for me, but in basic terms the SARS-CoV-2 RNA works in the same way as our own mRNA. Therefore, the viral RNA hijacks our own cellular machinery to replicate all the materials it needs to build new virions. These virions then exit our cells and move on to infect other cells and replicate more of the virus. And the cycle continues.</p><h4>How SARS-CoV-2 Affects Us</h4><p>OK, so we know how the virus replicates and spreads, but why, and how, does it make us so sick?</p><p>When a virus monopolises our cellular processes to replicate itself, it often disrupts the host cell’s homeostasis (the maintenance of an optimum environment) and causes irreparable damage to the cell, resulting in cell death.</p><p>In the case of SARS-CoV-2, the virus initially targets two types of lung cells: cells that produce mucus and ciliated cells, which use their cilia (hair-like structures that line the cell) to filter debris and pathogens with the mucus and move them up the respiratory tract so they can be swallowed and destroyed in the stomach. Just like SARS-CoV, SARS-CoV-2 kills these ciliated cells, which then allows debris and fluids to fill your airways and block your alveoli, the air sacs in your lungs where oxygen enters the blood, causing shortness of breath. In severe cases, this can lead to pneumonia and possible morbidity.</p><p>Until a vaccine is ready to be distributed, our immune system will do much of the work in fighting a SARS-CoV-2 infection. However, this can be a double-edged sword.</p><h4>The Immune Response</h4><p>Our bodies are attuned to recognising foreign substances, including viral infections of cells. A group of proteins, called <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25685">cytokines</a>, are released in areas of infection and ‘tag’ infected cells for destruction by our immune system, in an effort to stop the replication and spread of an infection. This is how the immune system also responds to coronaviruses, including SARS-CoV-2. And, for the most part, this response aids in the ultimate destruction of the virus. Early data, so far, suggests that around 82 per cent of cases present with milder symptoms.</p><p>However, sometimes our immune system overreacts, known as a hyperactive response. Usually, our immune system response is tightly regulated and targets only infected areas but in the event of a hyperactive immune response, our immune system struggles to differentiate between infected and healthy cells, and begins to destroy all cells in its path. This ultimately leads to more damage, rather than less. It is believed that hyperactive immune responses are worsening the effects of the infection in some patients, and increasing chances of severe pneumonia by increasing cellular debris and fluids in the lungs.</p><p>Immune system hyperactivity was also recorded in SARS-CoV patients, and it is believed that this hyperactivity was the cause of permanent damage to the lungs in the form of lesions and scar tissue. This damage is also being recorded in <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext">SARS-CoV-2 patients</a>.</p><h4>In Conclusion</h4><p>After days upon days of research, am I worried? Well, yes. No one wants to get sick. Am I scared? No. SARS-CoV-2 is an awful virus but it is no longer a mystery to me, and it’s that mystery that causes us so much anxiety.</p><p>At the moment, the WHO put the global death rate at 3.4 per cent, but there is speculation that this <a href="https://www.washingtonpost.com/health/coronavirus-mortality-rate/2020/03/06/b0c4cdfc-5efc-11ea-b014-4fafa866bb81_story.html">could come down</a> and, in some countries, become more in line with severe seasonal flu. In the U.K., the death rate is at around 0.73 per cent, with 273 confirmed cases and 2 confirmed deaths (at the time of writing this article).</p><p>So what should we do? You are likely asking asking, and the answer is simple: <em>don’t panic</em>. Remain calm and listen to the advice of your government and health officials.</p><h4>Further Reading</h4><p>Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X. and Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. <em>The Lancet</em>, 395<strong>(10223)</strong>, 507–513.</p><p>Chen, Y., Liu, Q. and Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. <em>Journal of Medical Virology</em>, 92<strong>(4)</strong>, 418–423.</p><p>Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang, Q. and Wu, J. (2020). Coronavirus infections and immune responses. <em>Journal of Medical Virology</em>. 92<strong>(4)</strong>, 424– 432.</p><p>National Geographic. (2020). Here’s what coronavirus does to the body. [online] Available at: https://www.nationalgeographic.co.uk/science-and-technology/2020/02/heres-what-coronavirus-does-body.</p><p>Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., Guo, Q., Song, T., He, J., Yen, H., Peiris, M. and Wu, J. (2020). SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. <em>New England Journal of Medicine</em>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5ccdad495f12" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Human Evolution Continues: Low Oxygen Environments]]></title>
            <link>https://medium.com/@stevensankey/human-evolution-continues-low-oxygen-environments-f708cb9796fc?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/f708cb9796fc</guid>
            <category><![CDATA[humans]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[evolution]]></category>
            <category><![CDATA[genetics]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Fri, 18 Oct 2019 22:14:18 GMT</pubDate>
            <atom:updated>2019-10-18T22:14:18.431Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Like all creatures, humans are still evolving in response to our environment. Some humans have even evolved to withstand low oxygen environments.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*Bekl6Q6tfv-ueOjYpT8q2g.jpeg" /></figure><p>We speak about evolution as if it’s something that previously happened and has been completed. That all that is now is all that will ever be. But this simply isn’t true. From tuskless elephants to antibiotic-resistant bacteria, evolution is constantly around us — the culmination of micro-changes in DNA — and humans are no exception. We are, afterall, organisms of this world and, like everything else, are subject to change.</p><p>Oxygen is one of, if not the, most essential substances humans need to survive. But in recent years, scientists have found that there are some humans who have evolved — and are continuing to evolve — to withstand low oxygen environments, such as high altitudes and under water.</p><h4>The Humans Who Breathe Less Oxygen</h4><p>In the mountains of Tibet lives the Tibetan highlanders, who live around 4,000 metres above sea level and breathe around 40% less oxygen than they would at sea level.</p><p>For the average lowlander (i.e. the average human) living in a 40% lower oxygen concentration environment would cause hypoxia of altitude (hypobaric hypoxia) and would likely result in fatigue, reproduction impairment and potentially lethal diseases. The most commonly known disease being chronic mountain sickness (CMS), which results in high concentrations of haemoglobin (the pigment which carries oxygen) in the blood caused by overproduction of red blood cells. CMS can also result in fluid in the lungs and swelling of the brain, both of which can lead to death. This is why mountain climbers take oxygen tanks with them when climbing to high altitudes.</p><p>However, the Tibetan highlanders don’t seem to suffer from the ill-effects of these high altitude low oxygen concentrations. In fact, they’ve been thriving for possibly thousands of years.</p><p>It is believed the Tibetan highlander’s have evolved a <a href="https://www.pnas.org/content/107/25/11459">variant of the <em>EPAS1</em></a> gene (also known as <em>HIF2α</em>). The <em>EPAS1</em> gene is part of a human biological mechanism which controls the body’s response to low blood oxygen concentration. This newly discovered variant, known as an allele, correlates with a marked reduction in response to hypoxic conditions; namely, no-to-little increase in blood haemoglobin concentration. In short, the Tibetan highlanders are not affected by mountain sickness until higher altitudes and lower oxygen concentrations.</p><p>It is theorised that living for generations in the low oxygen conditions of the Tibetan highlands has put significant selective pressure on the <em>EPAS1</em> gene. This has resulted in natural selection giving rise to humans more evolved to living with only 60% of the oxygen concentration than the average human.</p><h4>How Long Can You Hold Your Breath?</h4><p>Speaking of low oxygen, how long can you hold your breath underwater? Personally, not very long. After 30 seconds I feel incredibly uncomfortable and have to actively fight the urge to breathe. But the Bajau people, they are truly the champions.</p><p>The Bajau people — the ‘sea nomads’ — of Southeast Asia are extraordinary freedivers who have lived in the Indonesian region for over a thousand years. Most notably, they can hold their breath underwater for over 13 minutes.</p><p><a href="https://www.cell.com/cell/fulltext/S0092-8674(18)30386-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867418303866%3Fshowall%3Dtrue">In a recent study</a>, it has been found that the Bajau people have enlarged spleens, around 50% larger than that of their mainland cousins, the Saluan. The spleen is an organ which, when diving, releases a reserve of oxygenated red blood cells into the bloodstream. Therefore, the spleen aids in breath-holding underwater for extended periods. Enlarged spleens are also found in marine mammals, such as seals.</p><p>There is evidence so far that at least two genes may contribute to this extraordinary marine adaptation. <em>PDE10A</em> (Phosphodiesterase 10A) is one of these genes and it is known to be mutated in the Bajau people. <em>PDE10A</em> is associated with smooth muscle tissue contraction, like that of the spleen, and has been found to be related to spleen size. The larger the spleen, the larger the oxygenated blood reserve it can hold, ready for release when diving.</p><p>Another gene variant, <a href="https://www.physiology.org/doi/full/10.1152/ajpheart.00080.2016?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub%3Dpubmed"><em>BDKRB2</em> (Bradykinin receptor B2)</a>, which is associated with vasodilation and vasoconstriction (dilation and constriction of blood vessels) induced by the dive response, is thought to also contribute to the Bajau peoples’ marine adaptations. This variant of <em>BDKRB2</em> is thought to increase dive time by constricting blood vessels and preferentially oxygenating vital organs, such as the brain.</p><p>Adding together both a larger spleen with a larger oxygenated blood reserve, and a more adapted dive response to preferentially oxygenate vital organs, we can start to understand how the Bajau people are continually evolving to adapt to the hypoxic conditions of diving.</p><p>Evolution is often slow, to the point of almost imperceptibility, but it is prevalent and occurring all the time in nature. With our tools, we can now peer not just into the huge human evolutionary changes, such as our evolutionary divergence from Neanderthals, but into our more subtle adaptations that help us humans to adapt to our ever changing environments.</p><h4>Further Reading</h4><p>Baranova, T., Berlov, D., Glotov, O., Korf, E., Minigalin, A., Mitrofanova, A., Ahmetov, I. and Glotov, A. (2017). Genetic determination of the vascular reactions in humans in response to the diving reflex. <em>American Journal of Physiology-Heart and Circulatory Physiology</em>, 312<strong>(3)</strong>, H622-H631.</p><p>Beall, C., Cavalleri, G., Deng, L., Elston, R., Gao, Y., Knight, J., Li, C., Li, J., Liang, Y., McCormack, M., Montgomery, H., Pan, H., Robbins, P., Shianna, K., Tam, S., Tsering, N., Veeramah, K., Wang, W., Wangdui, P., Weale, M., Xu, Y., Xu, Z., Yang, L., Zaman, M., Zeng, C., Zhang, L., Zhang, X., Zhaxi, P. and Zheng, Y. (2010). Natural selection on EPAS1 (HIF2 ) associated with low hemoglobin concentration in Tibetan highlanders. <em>Proceedings of the National Academy of Sciences</em>, 107<strong>(25)</strong>, 11459–11464.</p><p>Ilardo, M., Moltke, I., Korneliussen, T., Cheng, J., Stern, A., Racimo, F., de Barros Damgaard, P., Sikora, M., Seguin-Orlando, A., Rasmussen, S., van den Munckhof, I., ter Horst, R., Joosten, L., Netea, M., Salingkat, S., Nielsen, R. and Willerslev, E. (2018). Physiological and Genetic Adaptations to Diving in Sea Nomads. <em>Cell</em>, 173<strong>(3)</strong>, 569–580.e15.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f708cb9796fc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Europe Gives the Go-Ahead on Cancer Treatment Pill]]></title>
            <link>https://medium.com/@stevensankey/europe-gives-the-go-ahead-on-cancer-treatment-pill-6bdc6a6c792?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/6bdc6a6c792</guid>
            <category><![CDATA[larotrectinib]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[vitrakvi]]></category>
            <category><![CDATA[therapy]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Sat, 05 Oct 2019 14:49:27 GMT</pubDate>
            <atom:updated>2019-10-05T14:53:10.106Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Europe have approved the use of a new tumour-agnostic cancer treatment pill which can be administered to both adults and children. But what does this mean and how does it work?</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/959/1*bzcMYQh5mP76A7iNHLE3MQ.jpeg" /><figcaption>(Vitrakvi not in image)</figcaption></figure><p>Lung cancer, skin cancer, breast cancer, prostate cancer… We are all familiar with many different types of cancer and there are many more for which we may not be. It’s likely that many of you will know the existential dread of sitting in a doctor’s office and just hoping the ‘C’ word doesn’t come up. And it’s likely that even more of you know about the standard treatments for cancer: chemotherapy and radiotherapy. But aren’t we all just hoping that one day we can take a few pills for our treatment? Well, we’re getting there.</p><p>In September, the European Medicines Agency approved Bayer’s <a href="https://www.hcp.vitrakvi-us.com/">Vitrakvi®</a>, otherwise known as the equally catchy name: larotrectinib. It was also approved in November 2018 by the U.S. Food and Drug Administration. Larotrectinib is one of a few new tumour-agnostic cancer treatments to be approved around the world recently. And best of all? It comes in the form of easy-to-swallow pills that both adults and children can be treated with.</p><p>Vitrakvi® had a <a href="https://www.hcp.vitrakvi-us.com/about-vitrakvi/efficacy/">75% overall response rate</a> in clinical trials. 53% of that being a partial response and 22% being a complete response to treatment. It has been designed to specifically treat <a href="https://www.hcp.vitrakvi-us.com/about-gene-fusion/shift-in-treatment/">NTRK gene fusion-related, solid tumour cancers</a> (don’t fret, this is explained later). The treatment is aimed as an alternative to high-risk operations and metastatic cancers (cancers which have spread to other areas of the body).</p><p>But what does this all mean and how does it all work?</p><h4>What Does It All Mean?</h4><p>Firstly, let’s tackle what all of the technical stuff really means.</p><p>Cancer is the result of damaged DNA triggering the uncontrolled division of cells, which divide and divide and eventually amass into a tumour. The body is a very tightly controlled system but mutations in certain genes, known as <a href="https://www.nature.com/scitable/topicpage/proto-oncogenes-to-oncogenes-to-cancer-883/">oncogenes</a> (onco- means relating to tumours), can cause this uncontrolled division, as well as disabling a cell’s natural self-destruct mechanism. Every cell in our body has the ability to essentially destroy itself if it becomes dysfunctional. Cancer is essentially dysfunctional cells which aren’t able to destroy themselves and which continually grow and divide.</p><p>The standard chemotherapy you may be familiar with is chosen based on the specific cancer, such as the aforementioned examples (i.e. lung cancer, skin cancer, etc.). These are example of tissue-specific cancers and are named after the bodily tissues where the cancer is found. However, <a href="https://www.cancer.net/blog/2018-12/tumor-agnostic-treatment-cancer-expert-perspective">tumour-agnostic</a> (also called tissue-agnostic) therapies will treat a specific type of cancer no matter what tissue it resides in. Tumour-agnostic therapies instead target cancers with specific genetic mutations which have caused said cancer to begin and a tumour to grow. This is also referred to as <a href="https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy">targeted therapy</a>.</p><p>In this case, larotrectinib targets cancers caused by neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Stay with me though, this is actually simpler than it sounds.</p><h4>How Does It All Work?</h4><p>Like most known genes, the <a href="https://esmoopen.bmj.com/content/1/2/e000023.full">NTRK genes</a> encode for proteins in our cells. In this case, NTRK1, NTRK2, and NTRK3 encode for neurotrophin receptor proteins (Tropomyosin receptor kinase)<strong> </strong>TrkA, TrkB, and TrkC, respectively. But don’t let all the abbreviations bog you down, these are essentially just proteins which sit in the membranes of our cells and bind to other proteins called neurotrophins. Hence why they are named neurotrophin receptors.</p><p>Neurotrophins, again, are just a different type of protein known as growth factors. As the name suggests, these proteins, when bound to receptors like the Trk proteins mentioned above, promote the <a href="https://esmoopen.bmj.com/content/1/2/e000023.full">growth and proliferation</a> of cells; more specifically in this case, neurons (nerve cells). And now we’ve come across our first red flag — growth and proliferation — because as we described earlier, cancer is essentially uncontrolled growth and division (proliferation) of cells. Whatsmore, neurotrophins are known to prevent programmed cell death; our second red flag, as many cancer cells lack the ability to destroy themselves — a process called <a href="https://www.nature.com/articles/cddis201520">programmed cell death</a>.</p><p>Finally, you may not be familiar with what gene fusions are. In the life cycle of a cell, there is a possibility for parts of two different genes to join and fuse together, creating a <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/fusion-gene">fusion gene</a>. This is a type of mutation. This new fusion gene will now encode a new fusion protein. However, NTRK gene fusions can lead to fusion proteins which are essentially permanently ‘switched on’ versions of the Trk protein receptors. Thus meaning, the affected cell will continuously receive signals to grow, divide, and never die. Ergo, cancer.</p><h4>How Does Larotrectinib Work?</h4><p>So, now we have an NTRK fusion gene, which encodes for a permanently ‘switched on’ version of the Trk protein receptor, causing a cell to continuously grow, divide, and never die, and therefore become cancerous. So how does larotrectinib treat this type of cancer?</p><p>Well, that’s actually the easy part to explain. Larotrectinib binds to, and inhibits the activity of, the Trk fusion protein. Without the ‘grow’, ‘divide’, and ‘don’t die’ signals from the Trk fusion protein, the cancer cell simply destroys itself in a process called programmed cell death. The idea being that the cancer kills itself and the tumour(s) shrinks.</p><h4>The Future</h4><p>There are more tumour-agnostic treatments in development right now and it’s likely we’ll see more approved for use in the coming years. This means that there could be more alternatives to high-risk operations and better treatment of metastatic cancers; which are the hardest cancers to treat, with the lowest survival rates.</p><p>The future of cancer treatment continues to look more and more hopeful.</p><h4>Further Reading</h4><p>Amatu, A., Sartore-Bianchi, A. and Siena, S. (2016). NTRKgene fusions as novel targets of cancer therapy across multiple tumour types. <em>ESMO Open</em>, 1<strong>(2)</strong>, e000023.</p><p>Chial, H. (2008) Proto-oncogenes to oncogenes to cancer. <em>Nature Education</em> 1<strong>(1), </strong>33.</p><p>Labi, V. and Erlacher, M. (2015). How cell death shapes cancer. <em>Cell Death &amp; Disease</em>, 6<strong>(3)</strong>, e1675.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6bdc6a6c792" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Brink of Extinction: The Tasmanian Devil]]></title>
            <link>https://medium.com/@stevensankey/brink-of-extinction-the-tasmanian-devil-89a756d17995?source=rss-1041e709ec62------2</link>
            <guid isPermaLink="false">https://medium.com/p/89a756d17995</guid>
            <category><![CDATA[tasmanian-devil]]></category>
            <category><![CDATA[extinction]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Steven Sankey]]></dc:creator>
            <pubDate>Tue, 29 Jan 2019 23:49:36 GMT</pubDate>
            <atom:updated>2019-01-30T00:03:34.531Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Many factors affect the Tasmanian devil but none so severe and urgent as Devil Facial Tumour Disease (DFTD) which has killed up to 90% of the wild population and continues to threaten the species with extinction.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*3fSmCIlPiR_6G2Dfk4joGg.jpeg" /></figure><p><em>Sarcophilus harrisii</em>, better known as the Tasmanian devil, is the largest carnivorous marsupial in the world and makes its home solely on, as you would imagine, the island of Tasmania, Australia.</p><p>Many factors affect the Tasmanian devil, such as habitat loss, introduced predators and roadkill, but none are more threatening to the entire species as Devil Facial Tumour Disease (DFTD).</p><p>DFTD is a very rare form of transmissible cancer found in Tasmanian devils. The cancer cells themselves act as the <a href="https://www.nature.com/articles/srep43827">infectious agent</a>, being transmitted from devil to devil most commonly via biting around the face. This behaviour is ubiquitous throughout the species and occurs when fighting over food and in mating.</p><p>Since its documented appearance in 1996, DFTD has killed approximately 90% of the population. So far, no subject has shown any natural immunity as the cancer <a href="http://www.jimmunol.org/content/jimmunol/195/1/23.full.pdf">does not seem to produce any immune response</a> from the animal. Mortality rates are 100%. The <a href="https://www.iucnredlist.org/species/40540/10331066">IUCN</a> has since listed the Tasmanian devil as “Endangered”.</p><p>The body has its own mechanisms in place to recognise foreign cells. When a foreign cell is located an immune response is triggered and the cell is usually destroyed. This is how animals, including humans, naturally fight bacterial infections and why blood transfusions require matching blood types. However, the DFTD cancer cells <a href="http://www.jimmunol.org/content/jimmunol/195/1/23.full.pdf">do not display any MHC-I</a> (major histocompatibility complex class I) proteins on the surface of their cells. These MHC-I proteins are what the body uses to recognise if a cell is native or foreign. Therefore, <a href="https://www.nature.com/articles/srep43827">without these MHC-I</a> proteins no immune response is triggered in the Tasmanian devil and the cancer is free to grow, proliferate and spread, ultimately causing death via organ failure or starvation.</p><p>Tasmanian devils are apex predators and therefore play a vital role in the Tasmanian ecosystem. Their extinction could cause a huge population growth in foxes, feral cats and <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590467/">possums</a> on the island, which could potentially result in further extinctions of other animals.</p><p>There is hope, however, as scientists around the world are exploring multiple avenues for a cure.</p><p>One avenue of research has been relatively successful in inducing the <a href="https://www.nature.com/articles/srep43827">expression of the MHC-I</a> proteins on the surface of the cancer cells. The study concluded that DFTD cancer cells possessed all the genetic machinery to produce and express MHC-I proteins on the cell surface. This allowed for the devil’s own immune response to destroy the cancer. However, the sample size was extremely small — an inherent problem when working with an endangered species — and there are still significant hurdles in this research before a potential vaccine can be produced en masse.</p><p>A <a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108%2818%2930539-7">recent study from January 2019</a>, published in the journal Cancer Cell, found overexpression of cell surface receptor proteins known as ERBB receptors. Human cancer cells also exhibit overexpression of ERBB receptors. These proteins bind to signalling molecules outside of the cell and thus initiate a cascade of processes within the cell which ultimately leads to the activation and/or repression of specific genes. In the case of DFTD, ERBB activates a series of processes which ultimately activates a protein called STAT3. STAT3 then activates genes related to metastasis (malignant growth) of the cancer cell (Figure 1).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*j3Wclnzm75fWPAOsTRVU7g.png" /><figcaption>Figure 1: A brief overview of ERBB receptor binding to a signalling molecule. A signalling cascade is initiated, ultimately activating STAT3. STAT3 initiates the expression of metastasis genes.</figcaption></figure><p>By inhibiting either the ERBB receptors or the STAT3 proteins from becoming activated, the study found that the cancer cells entered an arrested state. What’s more, the expression of MHC-I proteins on the cell surface was re-established with the inhibition of ERBB and STAT3, provoking a natural immune response in the devils. The study hypothesised that the overexpression of STAT3 inhibits the expression of MHC-I proteins.</p><p>There is still a way to go before an effective, large-scale treatment can be developed. In the meantime, captive breeding programs are in effect within Tasmania and mainland Australia in an effort to save the species and keep isolated populations disease free.</p><h3>References</h3><p><em>Hollings, T., McCallum, H., Kreger, K., Mooney, N. and Jones, M. (2015). Relaxation of risk-sensitive behaviour of prey following disease-induced decline of an apex predator, the Tasmanian devil. Proceedings of the Royal Society B: Biological Sciences, 282</em><strong><em>(1810)</em></strong><em>, p.20150124.</em></p><p><em>Kosack, L., Wingelhofer, B., Popa, A., Orlova, A., Agerer, B., Vilagos, B., Majek, P., Parapatics, K., Lercher, A., Ringler, A., Klughammer, J., Smyth, M., Khamina, K., Baazim, H., de Araujo, E., Rosa, D., Park, J., Tin, G., Ahmar, S., Gunning, P., Bock, C., Siddle, H., Woods, G., Kubicek, S., Murchison, E., Bennett, K., Moriggl, R. and Bergthaler, A. (2019). The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. Cancer Cell, 35</em><strong><em>(1)</em></strong><em>, 125–139.</em></p><p><em>Tovar, C., Pye, R., Kreiss, A., Cheng, Y., Brown, G., Darby, J., Malley, R., Siddle, H., Skjødt, K., Kaufman, J., Silva, A., Baz Morelli, A., Papenfuss, A., Corcoran, L., Murphy, J., Pearse, M., Belov, K., Lyons, A. and Woods, G. (2017). Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Scientific Reports, 7</em><strong><em>(1)</em></strong><em>.</em></p><p><em>Woods, G., Howson, L., Brown, G., Tovar, C., Kreiss, A., Corcoran, L. and Lyons, A. (2015). Immunology of a Transmissible Cancer Spreading among Tasmanian Devils. The Journal of Immunology, 195</em><strong><em>(1)</em></strong><em>, 23–29.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=89a756d17995" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>